Published in final edited form as:

Food Funct. 2018 September 19; 9(9): 4802–4813. doi:10.1039/c8fo00483h.

(–)-Epicatechin induced reversal of endothelial cell aging and improved vascular function: underlying mechanisms

Israel Ramirez-Sanchez^{a,b}, Christina Mansour^a, Viridiana Navarrete-Yañez^b, Marcos Ayala-Hernandez^b, Gustavo Guevara^b, Carmen Castillo^b, Maria Loreda^c, Moises Bustamante^{a,b}, Guillermo Ceballos^b, and Francisco J. Villarreal^{a,d}

^aDepartment of Medicine, School of Medicine, University of California, San Diego, La Jolla California, USA. fvillarr@ucsd.edu; Tel: +1 (858)-534-3630

^bSeccion de Estudios de Posgrado e Investigacion, Escuela Superior de Medicina, Instituto Politecnico Nacional, Mexico D.F., Mexico

^cEscuela de Medicina, Universidad Panamericana, Mexico D.F., Mexico

^dResearch Scientist, VA San Diego Healthcare, San Diego, CA, USA

Abstract

The consumption of cocoa products rich in (–)-epicatechin is associated with reduced cardiovascular risk and improved vascular function. However, little is known about (–)-epicatechin's effects on aged endothelium. In order to characterize the health restoring effects of (–)-epicatechin on aged endothelium and identify the underlying mechanisms, we utilized high passage number (*i.e.* aged) bovine coronary artery endothelial cells and aortas of 3 and 18 month old rats. We evaluated cell senescence (β -galactosidase), nitric oxide (NO) production through the endothelial nitric oxide synthase pathway, mitochondria related endpoints, citrate synthase activity and vascular relaxation. Cells were treated with water or (–)-epicatechin (1 μ M) for 48 h and rats orally with either water or (–)-epicatechin (1 mg kg⁻¹ day⁻¹) for 15 days. Senescence associated β -galactosidase levels doubled in aged cells while those treated with (–)-epicatechin only evidenced an ~40% increase. NO levels in cells decreased by ~33% with aging and (–)-epicatechin normalized them. Endothelial nitric oxide synthase phosphorylation levels paralleled these results. Aging increased total protein and synthase acetylation levels and (–)-epicatechin partially restored them to those of young cells by stimulating sirtuin-1 binding to the synthase. Phosphorylated sirtuin-1, mitofilin, oxidative phosphorylation complexes and transcriptional factor for mitochondria were reduced by ~40% with aging and were restored by (–)-epicatechin. (–)-Epicatechin enhanced acetylcholine induced aged aorta vasodilation and stimulated NO levels while reducing blood pressure. In conclusion, (–)-epicatechin reverses endothelial cell aging and restores key control elements of vascular function. These actions may partly explain the epidemiological evidence for the beneficial effects of cocoa consumption on the incidence of cardiac and vascular diseases.

Introduction

Cardiovascular disease (CVD) is a prominent, worldwide cause of morbidity and mortality. It is well recognized that the health of the endothelium is central to the underlying patho-

physiology of many types of CVD and that aging is an important contributor to the development of endothelial dysfunction.^{1,2} The identification of safe and effective agents that can promote the preservation and/or restoration of endothelial health is thus of high priority as their use may reduce CVD incidence.

Central to the preservation of vascular health is the endothelial nitric oxide synthase (eNOS), which under physiological conditions is responsible for the production of nitric oxide (NO).³ It has been demonstrated that vascular and endothelial cell function deteriorates with aging and this appears to be mainly due to a decrease in NO bioavailability.⁴ The causes of reduced bioavailability of NO as a function of aging are not completely understood. However, the acetylation of specific amino acid residues present in eNOS can trigger the loss of function by interfering with their phosphorylation.³ Aging is known to correlate with higher protein acetylation levels and loss of sirtuin-1 deacetylation activity, which may partly underlie the decreased eNOS activity.^{5,6}

The stimulation of NO synthesis by flavonoid-containing compounds has received widespread attention, as their effects appear to reduce CVD.^{7,8} Epidemiological studies indicate that the regular intake of cocoa derived products such as dark chocolate is inversely associated with the incidence of CVD including myocardial infarction, heart failure and stroke.^{9–11} We have reported on the capacity of the most abundant cocoa flavanol, (–)-epicatechin (Epi), to stimulate the production of NO and ascribed this effect to the ability of the flavanol to increase eNOS protein expression and activity levels.^{12,13} We have also reported on the capacity of Epi to notably mitigate markers of tissue aging and mitochondrial deterioration in senile mice.¹⁴ So far, no studies have examined the effects of Epi on aged endothelium NOS/NO levels and determined its ability to restore mitochondrial number and function.

With these goals in mind, we evaluated the effects of Epi on markers of cell senescence, NO production (*via* eNOS), acetylation levels, mitochondrial biogenesis and function as well as vasodilatory responses using bovine coronary artery endothelial cells and aortas isolated from young and aged animals. The results indicate that Epi is capable of reversing aging associated endothelial dysfunction and loss of mitochondrial density through effects on NO levels, which appear to be dependent on the acetylation/phosphorylation status of eNOS.

Materials and methods

Reagents

Primary bovine coronary artery endothelial cells were obtained from Cell Applications, Inc. Dulbecco's modified Eagle's medium, low glucose cell culture medium, trypsin, antibiotic/antimycotic solution, fetal bovine serum, and Hank's balanced salt solution (phenol red free) were from HyClone. Nonessential amino acid solution was from Mediatech Cellgro Inc. Phenol red free medium and low glucose cell culture medium were from Life Technologies, Inc. Bovine serum albumin, Tween-20, protease and phosphatase inhibitor cocktails, NG-nitro-L-arginine methyl ester hydrochloride (L-NAME), and Epi were from Sigma Aldrich, Inc. Polyvinylidene difluoride transfer membranes were from Millipore Inc. and Bradford assay reagent and acrylamide gels were from Bio-Rad, Inc. An Enhanced

Chemiluminescence Plus western blot detection kit and MitoTracker Green FM were from Thermo Fisher Scientific Inc. A citrate synthase activity assay kit and a MitoBiogenesis In-Cell ELISA kit (Colorimetric) were from Abcam, Inc. The senescence associated β -galactosidase staining kit was from Cell Signaling Technology Inc. and the Nitrate/Nitrite fluoro-metric assay kit was from Cayman Chemicals Inc. Primary antibodies against phospho-eNOS at Ser-1177, eNOS, β -tubulin, β -galactosidase, phospho-sirtuin, transcriptional factor mitochondria (TFAM), acetylated-lysine, and anti-rabbit and anti-mouse horseradish peroxidase-conjugated secondary antibodies were from Cell Signaling, Inc. Sirtuin-1 was from Santa Cruz Biotechnology, Inc. Primary antibodies against complex I, ATP synthase and mitofilin were from MitoSciences, Inc.

Cell culture

Cells were grown in a complete medium supplemented with 10% serum, 1% antibiotic/antimycotic solution, and 1% non-essential amino acids. Cells were maintained under a humidified atmosphere at 37°C with 5% CO₂ and 95% O₂. Passages 8–13 were used as a model for young endothelial cells while passages 31–35 were used as a model for aged endothelial cells. Cells were used for experiments at 80% confluence.

Cell treatment

For all experiments 24 h before treatment, growth medium was replaced with 1% serum medium, phenol red free, 1% antibiotic/antimycotic solution and 1% nonessential amino acids (starving medium). Epi treatment was applied to confluent cells using 1 μ M of Epi (diluted in water) for 48 h. Only vehicle was applied to the cells in the control group. Fresh starving medium and Epi were reapplied every 24 h. In select experiments, the NOS inhibitor L-NAME (300 μ M) was added to the cell medium 4 h previous to the addition of Epi and during the 48 h treatment with Epi.

Total protein extraction

Cells were washed three times with cold buffer (4 ml per plate) and lysed in 80 μ l of ice cold lysis buffer with protease and phosphatase inhibitor cocktails. Homogenates were sonicated for 15 min at 4°C, and centrifuged at 13 000g for 15 min to remove cell debris. The total protein concentration was measured in the supernatant using the Bradford method.

NO measurements

After 48 h treatment with Epi, 100 μ l of medium was collected to test NO levels using a fluorescent kit according to the manufacturer's instructions. Briefly, as the final products of NO *in vivo* are nitrite (NO₂⁻) and nitrate (NO₃⁻), the best estimation of total NO production is the sum of both NO₂⁻ and NO₃⁻. We used a nitrate/nitrite fluorometric assay as an accurate method for the measurement of the total nitrate/nitrite concentration. In the assay, the conversion of nitrate to nitrite utilizes nitrate reductase followed by the addition of an acidic solution of diaminonaphthalene (DAN) and NaOH, which enhances the detection of the fluorescent product, 1(*H*)-naphthotriazole. Measurement of the fluorescence generated was quantified using a fluorometer (FLx800, Bio-Tek Instruments). Nitrate/nitrite values were normalized against the total protein after the cells were scrapped from the plate and

lysed as described previously. Plasma (50 μ l) was collected from treated animals (see below) and NO levels were measured as above.

Senescence associated β -galactosidase activity

Young and aged cells were grown in 12 and 96 well plates. At 80% confluence, cells were treated for 48 h (control, Epi, Epi-L-NAME, and L-NAME). After the 48 h treatment, β -galactosidase activity was determined using a senescence associated β -galactosidase staining kit. The cells in the 12 well plates were used to visualize the characteristic blue staining of β -galactosidase activity under the microscope and images were taken. The cells in the 96 well plate were used to measure β -galactosidase activity *via* colorimetric analysis in a spectrophotometer (μ Quant, Bio-Tek Instruments, Inc.).

Western blot

In order to examine aging markers, the eNOS/NO pathway, and mitochondria related proteins, western blotting was performed. Cells were treated as described above. After treatment, cells were lysed and total protein was extracted. A total of 30 μ g of protein was loaded onto a 4–15% gel, electrotransferred, and incubated for 1 h followed by either 1–3 h incubation at room temperature or overnight incubation at 4°C with primary antibodies. Primary antibodies were typically diluted 1 : 1000 or 1 : 2000 in buffer plus 5% bovine serum albumin or 2% non-fat milk. Membranes were washed (3 $\times$ for 5 min) in buffer and incubated 1 h at room temperature in the presence of conjugated secondary antibodies diluted 1 : 5000 in a blocking solution. Membranes were again washed three times in buffer and immunoblots were developed. Band intensities were digitally quantified and normalized against β -tubulin.

Protein acetylation measurements

Immunoprecipitation was used to selectively isolate eNOS and quantify its acetylation status. Treated cells were lysed, total protein extracted, and protein content measured in the super-natant by the Bradford method. A total of 0.5 mg protein was precleared by adding 1 μ g of normal rabbit IgG control and 20 μ L protein agarose and mixed for 30 min (4°C) with a subsequent centrifugation at 12 000g for 10 min at 4°C. The supernatant was recovered and incubated at 4°C under mild agitation for 3 h with 10 μ L of an eNOS immunoprecipitation antibody. Twenty μ l of protein A/G-sepharose was added, and the mixture was incubated overnight at 4°C with shaking. The immunoprecipitation mixture was centrifuged at 12 000g for 15 min at 4°C and the supernatant was recovered and stored at 4°C for later analysis. The pellet was washed 3 $\times$ with extraction buffer under shaking for 15 min and centrifuged at 12 000g for 15 min at 4°C. The immunoprecipitation proteins in the pellet and those remaining in the supernatant were applied to a precast 4–15% sodium dodecyl sulfate–polyacryl-amide gradient gel electrophoresis for Western blotting against acetylated-lysine and sirtuin-1.

Mitochondrial complexes II and IV

Complex II and IV protein content was evaluated in cells using a MitoBiogenesis kit. Cells were seeded onto 96 well plates (50 000 per well) and cultured using standard medium.

Cells were incubated with vehicle, Epi, Epi and L-NAME, and L-NAME for 48 h. Cells were washed with buffer and fixed with 4% formaldehyde followed by washes with buffer. Cells were exposed to 0.5% acetic acid for 5 min to block endogenous alkaline phosphatase activity followed by washes with buffer and exposure to a permeabilization buffer for 30 min. Cells were exposed to a blocking solution and incubated with primary antibodies overnight at 4°C, followed by rinsing with wash buffer and incubation with secondary antibodies labeled with alkaline phosphatase and horseradish peroxidase for 2 h. Developing solutions (alkaline phosphatase for complex II and horseradish peroxidase for complex IV) were added and kinetic colorimetric signals measured using a spectrophotometer (μQuant, Bio-Tek Instruments, Inc.) using 405 nm for complex II and 600 nm for IV. Total absorbance values were normalized against cell number as derived from the use of Green Janus staining.

Citrate synthase activity (CS)

After 48 h of treatment, cells were lysed and total protein was extracted. An amount of 20 μg of protein was used for the assay. CS activity was determined by immunocapture using a citrate synthase kit in a 96 well plate according to the manufacturer's instructions. The activity of the enzyme captured in the wells was determined by color development at 412 nm. All samples were tested in duplicate and the activity was measured at room temperature.

MitoTracker green assay

Mitochondria were labeled using the cell-permeable probe MitoTracker Green FM dye. Cells were plated in 96-well plates (1×10^4 cells per well). After 24 h of incubation with growth medium, cells were incubated with Epi, Epi and L-NAME, and L-NAME for 48 h. Cells were washed with 100 μL serum-free DMEM and stained with 200 nM MitoTracker Green FM dissolved in Hank's buffered saline solution for 30 min. Unstained control cells were incubated with serum-free medium containing no dye but treatment or vehicle as the stained samples. After staining, cells were washed three times with 100 μL serum-free medium and thereafter 100 μL of buffer was added to each well. For the microplate assay, staining was detected on a fluorescence microplate reader (μQuant from Bio-Tek Instruments) (excitation 485 nm, emission 520 nm), and fluorescence was subtracted from the unstained control and expressed relative to cell number.

Animals

Aortas from young (3 month old, 250–300 g) or aged (18 month old, 500–600 g) male Wistar rats were employed for the *ex vivo* evaluation of Epi's vascular effects. Rats were allocated into 4 groups (8 animals per group): (1) young control (vehicle), (2) young Epi, (3) aged control, and (4) aged Epi. Animals were provided with either vehicle (water) or Epi ($1 \text{ mg kg}^{-1} \text{ day}^{-1}$) for 15 days. Animals were maintained at room temperature (18–25°C) and on a 12 h light/dark cycle, with food and water being provided *ad libitum*. Animals were handled following guidelines and in full compliance with the Mexican federal regulations for animal experimentation and care and the good practices of the Comité Interno para el Cuidado y Uso de los Animales de Laboratorio with regard to research using animals. The Institutional Committee on Animal Research of the Escuela de Medicina del Instituto Politecnico Nacional approved the experiments.

Blood pressure

A non-invasive method to measure systolic blood pressure was performed using a pressure transducer placed on the tail of the animal with values digitally recorded.

Vascular reactivity

Under anesthesia (60 mg kg⁻¹ pentobarbital), animals were decapitated and the thoracic aorta from the diaphragm to the aortic arch was isolated. Aortas were immediately submerged in cold Krebs solution to remove all adjacent connective tissue, and then cut into ring segments (4–5 mm long), which were then mounted on two stainless steel hooks within an isolated organ chamber. One of the hooks was fixed to the bottom of the chamber and the other to a transducer linked to a Biopac System apparatus for registering changes in tension (force). The isolated organ chamber contained 10 ml of Krebs bicarbonate solution. The chamber was maintained at a constant temperature of 37°C, a pH of 7.4 and a continuous bubbling with a mixture of 95% O₂ and 5% CO₂. Aorta rings were pre-contracted using phenylephrine (1×10^{-11}), and standard concentration–response curves of acetylcholine (1×10^{-11} – 1×10^{-4} M) were constructed to analyze the effect of 15 days of Epi treatment on the vascular reactivity of the pre-contracted aortas.

Immunofluorescence

In order to detect post-translational modifications (phosphorylation and acetylation) on eNOS in aging, we used immunofluorescence staining of dissected aortas from young and aged rats. Aortas were cut into 0.5 cm fragments. Each vessel fragment was filled with tissue freezing medium and frozen in liquid nitrogen-isopentane. Cryosections (7 µm in thickness) from each vessel were permeabilized for 3 min with 0.3% Triton X-100. After incubation with blocking solution (5% bovine serum albumin in phosphate-buffered solution [PBS]) for 1 h at room temperature, cryosections were incubated for 3 h with one primary antibody (single staining) or two primary antibodies (double staining) at room temperature. After several washes, sections were incubated with a fluorescent secondary antibody for 1 h at room temperature. After rinsing with buffer, sections were mounted using Vectashield medium, counterstained to visualize nuclei (Vector Laboratories, Burlingame, Calif., USA) and observed using a fluorescence microscope.

Data analysis

For cell culture experiments, at least three independent experiments each in triplicate were performed. For animal studies, six rats per group were included. The results are expressed as the mean ± standard error of the mean (SEM). Data analysis was performed by one-way analysis of variance (ANOVA) followed by Tukey's *post hoc* test using GraphPad Prism (GraphPad Software Inc., San Diego, USA). A *p* value of 0.05 was considered to be statistically significant.

Results

Fig. 1A shows β-galactosidase staining observed in young and aged cells while Fig. 1B reports on their quantification using 96 well stained plates. At the baseline, increased staining levels are observed in aged *vs.* young cells, which were reduced by Epi treatment.

The use of L-NAME in untreated aged cells further increased staining and was able to block the effects of Epi. In young cells, Epi and/or L-NAME treatments did not apparently alter β -galactosidase staining. As illustrated in Fig. 1C, a similar pattern of changes was observed in β -galactosidase protein levels measured by western blotting whereby young cells evidenced low levels of staining regardless of the treatment applied. Aged cells demonstrated significantly higher protein levels vs. young and Epi treatment suppressed these increases. Fig. 2A and B report on the effects triggered by aging and treatments on NO and p-eNOS levels, respectively. Treatment of young cells with Epi significantly increased NO levels. With aging, cells evidenced significantly reduced (~40%) NO levels and Epi was able to restore NO levels to those of young cells. p-eNOS results essentially paralleled those noted for NO levels.

Fig. 3A and B show the effects of aging on sirtuin-1. In young cells, Epi stimulated the phosphorylation of sirtuin-1 by ~40%. Aging led to a decrease of ~50% in p-sirtuin-1 levels, which were restored to those of young cells with Epi. Fig. 4A reports on the total protein acetylation levels of young vs. aged cells. While no differences were noted in young cells, aging led to a ~3 fold increase in total protein acetylation, which was essentially normalized using Epi treatment. Fig. 4B and C plots eNOS acetylation levels in young and aged cells as well as the levels of sirtuin-1 that were associated with eNOS following immunoprecipitation. While no effects were noted in young cells, eNOS acetylation essentially doubled in aged cells and was partially restored to young cell levels by Epi treatment. Sirtuin-1 levels associated with eNOS decreased by ~60% in aged cells and were essentially restored to those of young cells by Epi treatment.

Fig. 5A and B illustrate the effects of aging and treatments on markers of mitochondrial biogenesis, cristae and oxidative phosphorylation (TFAM, mitofilin, and complex V). In young cells, an increase of ~25% was noted with Epi treatment in all proteins. Aging led to ~50% reduction in the protein levels and treatment with Epi fully restored levels to those of young cells. Fig. 6A/B reports on the effects of aging and treatment on oxidative phosphorylation of complexes II and IV. In young cells, a stimulation was induced with Epi. Aged cells have a decrease of ~30% in protein levels that were fully restored by Epi. Fig. 6C reports on the mitochondrial function as assessed by citrate synthase activity. A stimulatory effect was noted with Epi in young cells. In aged cells, there was a ~25% decrease in citrate synthase activity vs. young. With Epi treatment, levels were comparable to those of young. To quantify the effects of aging and Epi treatment on mitochondrial mass (density), MitoTracker green staining of cells was used and quantified using a fluorescence plate reader. As shown in Fig. 6D, aged cells evidence less MitoTracker staining density vs. young cells. Epi treatment of young cells stimulated staining levels while in aged cells it restored their intensity to those of young cells. As noted in Fig. 2–6, in all cases, pre-treatment of cells with L-NAME was able to block Epi induced stimulation, thus evidencing the critical role played by eNOS.

Fig. 7A reports on systolic blood pressure levels in young and aged rats and Fig. 7B reports on the corresponding plasma NO levels detected. Aged animals evidenced higher systolic pressures (~130 vs. 100 mmHg, aged vs. young) and Epi treatment was able to normalize their levels to those of young rats. In aged animals, plasma NO levels were reduced by ~50%

and Epi was able to restore them to those of young rats (while also significantly stimulating them in this group). Fig. 7C and D show the effect of Epi treatment in excised aortas. In aortic rings from young (C) and aged (D) animals, a vasodilatory effect of acetylcholine was evidenced at concentrations ranging from 10^{-11} to 10^{-4} mol L⁻¹. The calculated ED₅₀ values in young ($2.1 \cdot 10^{-7}$ mol L⁻¹) vs. aged ($5.8 \cdot 10^{-7}$ mol L⁻¹) indicate a mild impairment in aged animal aortas' vasorelaxation response. An enhanced response was triggered by Epi treatment in both groups of animals; ED₅₀ in young animals ($6.6 \cdot 10^{-10}$ M) vs. aged ($1.6 \cdot 10^{-8}$ mol L⁻¹) suggest an increased effect in the aortic rings from young animals, reaching a maximal level of relaxation of ~1.5 g vs. 1.2 g in the aortas from aged rats. Fig. 8A and B show p-eNOS levels as detected by immunofluorescence staining of the aortic endothelium in the same animals, evidencing parallel results to those noted for NO levels. Fig. 8C illustrates the eNOS and total protein acetylation staining levels in the endothelium of aortas of young and aged rats. With aging, a reduction in total eNOS levels was noted while total protein acetylation increased. Epi treatment was able to increase eNOS levels while reducing total protein acetylation in endothelial cells.

Discussion

The results indicate that in aged endothelium, a reduction in NO production occurs, which is associated with decreased eNOS phosphorylation at activation sites coupled to higher levels of amino acid residue acetylation. Aged endothelium also evidences decreased levels for regulators of mitochondria biogenesis including sirtuin-1 and organelle function. Epi restored aged endothelium and rat NO production to levels comparable to those of young cells/animals. Effects were associated with increased levels of eNOS phosphorylation, reduced acetylation, and improved mitochondrial function. These results follow the ability of Epi to restore sirtuin-1 protein levels and deacetylase activity and thus mitigate aging induced loss of vascular function.

The restoration of physiological levels of NO to those comparable to a younger phenotype is seen as an appealing strategy to mitigate CVD development. Recommended strategies include aerobic exercise and intake of foods rich in dietary nitrates such as beetroot juice.^{15–18} However, exercise activity may be difficult to maintain, in particular, later in life. Natural supplements such as resveratrol have been considered and tested with modest to null results.^{19–21} Interestingly, there is a greater level of recognition for the pleiotropic effects of statins, which include positive effects on the eNOS regulatory system.²² However, statin use (beyond cholesterol reducing effects) remains controversial in particular, since a large percentage of the population is opposed to consuming drugs for possibly decades where the adverse effects of such compounds may also become evident (myopathy and type 2 diabetes).^{23,24} The use of androgen precursors and estrogen supplementation has also been considered to mitigate vascular inflammation and/or restoring function.^{25,26} However, the use of hormone supplementation remains controversial.²⁷

Epidemiological studies associate cocoa product consumption with reduced cardiometabolic risk.^{28,29} Clinical studies using cocoa products document positive effects on vascular structure and/or function in menopausal women, smokers and those with ischemic heart disease.^{30,31} Studies also demonstrate that cocoa consumption can mobilize angiogenic

cells³² and improve memory following 3 months of supplementation in normal 60-year-old subjects while increasing the brain blood volume.³³ Evidence has been generated regarding the mechanisms that may underlie the vascular effects of Epi. We demonstrated that human coronary artery endothelial cells treated with 1 μ M Epi stimulate serine 633 and 1177 eNOS phosphorylation and the dephosphorylation at threonine 495, thus activating the enzyme. Epi also promotes eNOS uncoupling from caveolin-1 *via* its interaction with heat shock protein 90 and binding to calmodulin-1 leading to its activation.¹² Furthermore, we reported on Epi's unique ability to induce eNOS activation in a calcium independent manner.¹³ We also established that eNOS amino acid residue glycosylation levels are higher (yielding enzyme inactivation) in obese mice and human coronary artery endothelial cells exposed to high glucose and that Epi is able to reduce these to those of control samples.³⁴ These results demonstrate the versatility of this compound in its ability to activate eNOS and thus restore age-related NO decline *via* non-redundant actions.

An accepted marker of cell aging is β -galactosidase activity.³⁵ In this study, β -galactosidase activity increased with cell passage number and Epi treatment mitigated the effect. The use of L-NAME further increased the β -gal activity differences evidencing the dependence of cell aging on NO bio-availability. Aging of cells led to a diminished capacity to produce NO, which correlated closely with reduced levels of eNOS phosphorylation. Epi treatment was able to restore NO and eNOS phosphorylation levels to those typical of young cells. These effects are comparable to those reported for statins in human umbilical cord endothelial cells aged with hydrogen peroxide treatment.³⁶

The results indicate that loss of sirtuin-1 mediated deacetylase activity underlies at least in part the aging induced loss of eNOS function. A reduced level of sirtuin-1 activity may be secondary to decreases in protein levels and/or its phosphorylation. Here, we report on the capacity of Epi to restore sirtuin-1 protein and phosphorylation levels, effects that can also be triggered by agents such as statins and resveratrol.^{36,37} Aging is also associated with higher eNOS acetylation, an effect that was also suppressed by Epi treatment and was linked to the enhanced protein-protein interaction of eNOS with sirtuin-1. As reported by Ota *et al.*, statins also increase sirtuin-1 expression and its physical coupling to eNOS.³⁶

In close association with the health status of the endothelial cells are the indicators of mitochondrial structural integrity and function. In our study, we assessed protein levels for a recognized regulator of mitochondrial biogenesis (TFAM), cristae structure (mitofilin), oxidative phosphorylation (complex V) and function (CS activity) including indicators of mitochondrial biogenesis markers (complex II/IV) and abundance (MitoTracker Green). In all cases, aging depleted the levels of these endpoints, which were fully restored by Epi. Thus, treatment with Epi appears to reinstate the metabolic oxidative capacity of the cells to that comparable to young ones. The coupling of the increases in mitochondria abundance, structure and function in endothelial cells to enhanced NO levels has also been demonstrated using resveratrol and statins.^{36,38} As demonstrated by Nisoli *et al.*, NO effects appear to be partly dependent on increases in cyclic guanosine mono-phosphate and induction of peroxisome proliferator-activated receptor γ coactivator 1 α as mitochondrial biogenesis induced by exposure to cold was markedly reduced in brown adipose tissue of eNOS null-

mutant mice, which had a reduced metabolic rate and accelerated weight gain vs. wild-type mice.³⁹

Crucial to support our *in vitro* data were responses triggered by Epi *in vivo*. In aged rats, an increase in blood pressure was noted, suggesting an increased stiffness and/or endothelial dysfunction, which was corroborated by decreased acetylcholine-induced vasodilation. Epi partly restored the functional responses (blood pressure and vasodilation) to those noted in young animals and these changes correlated with enhanced endothelial eNOS phosphorylation and reduced acetylation. A limitation of this study relates to the fact that when Epi is provided orally, it is readily metabolized and Epi metabolites can reach “high” levels in blood and trigger similar effects on the endothelium as to the native molecule.⁴⁰ Ultimately, in the *in vivo* setting, the additive role of each chemical entity (including native Epi) likely accounts for the “final” response noted after the flavanol is provided orally. This scenario is not distinct from that given by the use of drugs such as losartan in cell culture where the metabolites that are generated *in vivo* are as or more potent than the native compound.⁴¹

Besides endothelium effects, our group has published a series of studies documenting the positive impact that either cocoa or Epi can provide. In rodent models of myocardial infarction, obesity/insulin resistance and aging, we have documented the protective effects that 1 mg kg⁻¹ day⁻¹ of Epi triggers on multiple endpoints and in many organs. Treatment reduces infarct size, stimulates angiogenesis, ameliorates obesity-induced indicators of cardiometabolic dysregulation, improves multiple indicators of oxidative stress, as well as mitochondrial, skeletal and cardiac structure and function in normal and aged animals.^{14,34,42–45} In proof-of-concept studies, cocoa supplementation (that yields blood levels similar to those of 1 mg kg⁻¹ day⁻¹ of Epi ~300 nM) improves multiple indicators of skeletal muscle structure and function (including NOS and NO levels) in patients with heart failure and type 2 diabetes.⁴⁶ In normal, sedentary subjects, cocoa supplementation enhances multiple indicators of muscle metabolism while improving organ function.⁴⁷ Epi can also increase muscle strength in normal subjects and significantly reduces triglyceride levels in those with hypertriglyceride mia.^{48,49} A common central theme underlying Epi’s effects are improvements in NO levels and the stimulation of mitochondria.

In conclusion, we demonstrate that a compound found in high concentrations in cocoa reverses aging-associated loss of vascular function. The consumption of products enriched with Epi is likely to promote preservation of vascular health and positively impact society’s well being. Greater insight as to the potential of flavanols to exert a positive impact on CVD risk is likely to be gained from the ongoing COcoa Supplement and Multivitamin Outcomes Study (COSMOS) trial whereby 18 000 volunteers are to be provided high flavanol cocoa capsules for 5 years. If outcomes are positive, this trial may pave the way for greater appreciation of the positive impact that cocoa flavanol supplementation may have in a range of diseases.

Conflicts of interest

Dr Villarreal is a co-founder and stockholder (Dr Ceballos) of Cardero Therapeutics, Inc. The co-authors Ramirez-Sanchez, Mansour, Navarrete, Ayala, Guevara, Castillo, Loredó and Bustamante have no disclosures.

References

1. Park KH and Park WJ, Endothelial Dysfunction: Clinical Implications in Cardiovascular Disease and Therapeutic Approaches, *J Korean Med Sci*, 2015, 30, 1213–1225. [PubMed: 26339159]
2. Herrera MD, Mingorance C, Rodriguez-Rodriguez R and Alvarez de Sotomayor M, Endothelial dysfunction and aging: an update, *Ageing Res. Rev*, 2010, 9, 142–152. [PubMed: 19619671]
3. Forstermann U and Sessa WC, Nitric oxide synthases: regulation and function, *Eur. Heart J*, 2012, 33, 837a–837d.
4. Seals DR, Jablonski KL and Donato AJ, Aging and vascular endothelial function in humans, *Clin. Sci*, 2011, 120, 357–375. [PubMed: 21244363]
5. Kitada M, Ogura Y and Koya D, The protective role of Sirt1 in vascular tissue: its relationship to vascular aging and atherosclerosis, *Aging*, 2016, 8, 2290–2307. [PubMed: 27744418]
6. Donato AJ, Magerko KA, Lawson BR, Durrant JR, Lesniewski LA and Seals DR, SIRT-1 and vascular endothelial dysfunction with ageing in mice and humans, *J. Physiol*, 2011, 589, 4545–4554. [PubMed: 21746786]
7. Vita JA, Polyphenols and cardiovascular disease: effects on endothelial and platelet function, *Am. J. Clin. Nutr*, 2005, 81, 292S–297S. [PubMed: 15640493]
8. Vauzour D, Rodriguez-Mateos A, Corona G, Oruna-Concha MJ and Spencer JP, Polyphenols and human health: prevention of disease and mechanisms of action, *Nutrients*, 2010, 2, 1106–1131. [PubMed: 22254000]
9. Galleano M, Oteiza PI and Fraga CG, Cocoa, chocolate, and cardiovascular disease, *J. Cardiovasc. Pharmacol*, 2009, 54, 483–490. [PubMed: 19701098]
10. Corti R, Flammer AJ, Hollenberg NK and Luscher TF, Cocoa and cardiovascular health, *Circulation*, 2009, 119, 1433–1441. [PubMed: 19289648]
11. Kwok CS, Boekholdt SM, Lentjes MA, et al., Habitual chocolate consumption and risk of cardiovascular disease among healthy men and women, *Heart*, 2015, 101, 1279–1287. [PubMed: 26076934]
12. Ramirez-Sanchez I, Maya L, Ceballos G and Villarreal F, (–)-epicatechin activation of endothelial cell endothelial nitric oxide synthase, nitric oxide, and related signaling pathways, *Hypertension*, 2010, 55, 1398–1405. [PubMed: 20404222]
13. Ramirez-Sanchez I, Maya L, Ceballos G and Villarreal F, (–)-Epicatechin induces calcium and translocation independent eNOS activation in arterial endothelial cells, *Am. J. Physiol.: Cell Physiol*, 2011, 300, C880–C887. [PubMed: 21209365]
14. Moreno-Ulloa A, Nogueira L, Rodriguez A, et al., Recovery of Indicators of Mitochondrial Biogenesis, Oxidative Stress, and Aging With (–)-Epicatechin in Senile Mice, *J. Gerontol., Ser. A*, 2015, 70, 1370–1378.
15. Webb AJ, Patel N, Loukogeorgakis S, et al., Acute blood pressure lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to nitrite, *Hypertension*, 2008, 51, 784–790. [PubMed: 18250365]
16. Kapil V, Milsom AB, Okorie M, et al., Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived NO, *Hypertension*, 2010, 56, 274–281. [PubMed: 20585108]
17. Sobko T, Marcus C, Govoni M and Kamiya S, Dietary nitrate in Japanese traditional foods lowers diastolic blood pressure in healthy volunteers, *Nitric Oxide*, 2010, 22, 136–140. [PubMed: 19887114]
18. Lidder S and Webb AJ, Vascular effects of dietary nitrate (as found in green leafy vegetables and beetroot) via the nitrate-nitrite-nitric oxide pathway, *Br. J. Clin. Pharmacol*, 2013, 75, 677–696. [PubMed: 22882425]
19. Schmitt CA, Heiss EH and Dirsch VM, Effect of resveratrol on endothelial cell function: Molecular mechanisms, *BioFactors*, 2010, 36, 342–349. [PubMed: 20730905]
20. Labinskyy N, Csiszar A, Veress G, et al., Vascular dysfunction in aging: potential effects of resveratrol, an anti-inflammatory phytoestrogen, *Curr. Med. Chem*, 2006, 13, 989–996. [PubMed: 16611080]

21. Yoshino J, Conte C, Fontana L, et al., Resveratrol supplementation does not improve metabolic function in non-obese women with normal glucose tolerance, *Cell Metab*, 2012, 16, 658–664. [PubMed: 23102619]
22. Davignon J, Beneficial cardiovascular pleiotropic effects of statins, *Circulation*, 2004, 109, III39–43. [PubMed: 15198965]
23. Reiner Z, Resistance and intolerance to statins, *Nutr., Metab. Cardiovasc. Dis*, 2014, 24, 1057–1066. [PubMed: 24996502]
24. Parida S, Swain TR, Routray SN and Maiti R, Effect of Atorvastatin on Glycaemic Parameters in Normoglycaemic and Prediabetic Subjects: A Prospective, Panel Study, *J. Clin. Diagn. Res*, 2017, 11, FC04–FC09.
25. Kawano H, Yasue H, Hirai N, et al., Effects of transdermal and oral estrogen supplementation on endothelial function, inflammation and cellular redox state, *Int. J. Clin. Pharmacol. Ther*, 2003, 41, 346–353. [PubMed: 12940591]
26. Xing D, Nozell S, Chen YF, Hage F and Oparil S, Estrogen and mechanisms of vascular protection, *Arterioscler., Thromb., Vasc. Biol*, 2009, 29, 289–295. [PubMed: 19221203]
27. Nelson HD, Humphrey LL, Nygren P, Teutsch SM and Allan JD, Postmenopausal hormone replacement therapy: scientific review, *J. Am. Med. Assoc*, 2002, 288, 872–881.
28. Buijsse B, Weikert C, Drogan D, Bergmann M and Boeing H, Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults, *Eur. Heart J*, 2010, 31, 1616–1623. [PubMed: 20354055]
29. McCullough ML, Peterson JJ, Patel R, Jacques PF, Shah R and Dwyer JT, Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults, *Am. J. Clin. Nutr*, 2012, 95, 454–464. [PubMed: 22218162]
30. Okamoto T, Kobayashi R, Natsume M and Nakazato K, Habitual cocoa intake reduces arterial stiffness in postmenopausal women regardless of intake frequency: a randomized parallel-group study, *Clin. Interventions Aging*, 2016, 11, 1645–1652.
31. Heiss C, Kleinbongard P, Dejam A, et al., Acute consumption of flavanol-rich cocoa and the reversal of endothelial dysfunction in smokers, *J. Am. Coll. Cardiol*, 2005, 46, 1276–1283. [PubMed: 16198843]
32. Heiss C, Jahn S, Taylor M, et al., Improvement of endothelial function with dietary flavanols is associated with mobilization of circulating angiogenic cells in patients with coronary artery disease, *J. Am. Coll. Cardiol*, 2010, 56, 218–224. [PubMed: 20620742]
33. Brickman AM, Khan UA, Provenzano FA, et al., Enhancing dentate gyrus function with dietary flavanols improves cognition in older adults, *Nat. Neurosci*, 2014, 17, 1798–1803. [PubMed: 25344629]
34. Ramirez-Sanchez I, Rodriguez A, Moreno-Ulloa A, Ceballos G and Villarreal F, (–)-Epicatechin-induced recovery of mitochondria from simulated diabetes: Potential role of endothelial nitric oxide synthase, *Diabetes Vasc. Dis. Res*, 2016, 13, 201–210.
35. Debacq-Chainiaux F, Erusalimsky JD, Campisi J and Toussaint O, Protocols to detect senescence-associated beta-galactosidase (SA- β gal) activity, a biomarker of senescent cells in culture and in vivo, *Nat. Protoc*, 2009, 4, 1798–1806. [PubMed: 20010931]
36. Ota H, Eto M, Kano MR, et al., Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway, *Arterioscler., Thromb., Vasc. Biol*, 2010, 30, 2205–2211. [PubMed: 20705918]
37. Arunachalam G, Yao H, Sundar IK, Caito S and Rahman I, SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol, *Biochem. Biophys. Res. Commun*, 2010, 393, 66–72. [PubMed: 20102704]
38. Csiszar A, Labinskyy N, Pinto JT, et al., Resveratrol induces mitochondrial biogenesis in endothelial cells, *Am. J. Physiol.: Heart Circ. Physiol*, 2009, 297, H13–H20. [PubMed: 19429820]
39. Nisoli E, Clementi E, Paolucci C, et al., Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide, *Science*, 2003, 299, 896–899. [PubMed: 12574632]
40. Schroeter H, Heiss C, Balzer J, et al., (–)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans, *Proc. Natl. Acad. Sci. U. S. A*, 2006, 103, 1024–1029. [PubMed: 16418281]

41. Dickstein K, Timmermans P and Segal R, Losartan: a selective angiotensin II type 1 (AT1) receptor antagonist for the treatment of heart failure, *Expert Opin. Invest. Drugs*, 1998, 7, 1897–1914.
42. Yamazaki KG, Taub PR, Barraza-Hidalgo M, et al., Effects of (–)-epicatechin on myocardial infarct size and left ventricular remodeling after permanent coronary occlusion, *J. Am. Coll. Cardiol*, 2010, 55, 2869–2876. [PubMed: 20579545]
43. Ramirez-Sanchez I, Nogueira L, Moreno A, et al., Stimulatory effects of the flavanol (–)-epicatechin on cardiac angiogenesis: additive effects with exercise, *J. Cardiovasc. Pharmacol*, 2012, 60, 429–438. [PubMed: 22833114]
44. Gutierrez-Salmean G, Ortiz-Vilchis P, Vacaseydel CM, et al., Effects of (–)-epicatechin on a diet-induced rat model of cardiometabolic risk factors, *Eur. J. Pharmacol*, 2014, 728, 24–30. [PubMed: 24491839]
45. Nogueira L, Ramirez-Sanchez I, Perkins GA, et al., (–)-Epicatechin enhances fatigue resistance and oxidative capacity in mouse muscle, *J. Physiol*, 2011, 589, 4615–4631. [PubMed: 21788351]
46. Taub PR, Ramirez-Sanchez I, Ciaraldi TP, et al., Alterations in skeletal muscle indicators of mitochondrial structure and biogenesis in patients with type 2 diabetes and heart failure: effects of epicatechin rich cocoa, *Clin. Transl. Sci*, 2012, 5, 43–47. [PubMed: 22376256]
47. Taub PR, Ramirez-Sanchez I, Patel M, et al., Beneficial effects of dark chocolate on exercise capacity in sedentary subjects: underlying mechanisms. A double blind, randomized, placebo controlled trial, *Food Funct*, 2016, 7, 3686–3693. [PubMed: 27491778]
48. Gutierrez-Salmean G, Ciaraldi TP, Nogueira L, et al., Effects of (–)-epicatechin on molecular modulators of skeletal muscle growth and differentiation, *J. Nutr. Biochem*, 2014, 25, 91–94. [PubMed: 24314870]
49. Gutierrez-Salmean G, Meaney E, Lanaspá MA, et al., A randomized, placebo-controlled, double-blind study on the effects of (–)-epicatechin on the triglyceride/HDLc ratio and cardiometabolic profile of subjects with hypertriglyceridemia: Unique in vitro effects, *Int. J. Cardiol*, 2016, 223, 500–506. [PubMed: 27552564]

Fig. 1.

β-Galactosidase staining, activity, and protein levels using young and aged control (Ctrl), (–)-epicatechin and L-NAME treated cells. (A) Staining assay for visualizing β-galactosidase activity in 6 well cell culture plates. (B) β-Galactosidase activity in 96 well stained plates. Absorbance values were normalized against the number of cells. (C) β-Galactosidase and β-tubulin (loading control) protein levels evaluated by western blotting. (Values are expressed as the mean ± SEM; $n = 4$ per group, * $p < 0.05$ vs. young control, and [^] vs. aged control). Senescence associated β-galactosidase = SA-β-Gal, control = Ctrl, (–)-epicatechin = Epi, optical density = O.D.

Fig. 2.

Effects of aging and (–)-epicatechin treatment on nitric oxide and eNOS. (A) Young and aged cells were treated with Epi, L-NAME, or Epi and L-NAME and the nitric oxide (NO) levels were measured after 48 h. NO (nitrite/nitrate, nmol per mg protein) levels were normalized against protein content. (B) Under the same conditions, total eNOS and p-eNOS (Ser-1179) expression levels were evaluated by western blotting. (C) The p-eNOS/eNOS ratio was calculated. eNOS and p-eNOS protein levels were normalized against β -tubulin. (Values are expressed as the mean $\pm$ SEM; $n = 3$ per group, * $p < 0.05$ vs. young control, and [^] vs. aged control). (–)-Epicatechin = Epi, nitric oxide = NO.

Fig. 3.

Effects of aging and (-)-epicatechin treatment on sirtuin-1 and p-sirtuin-1 protein levels. Young and aged cells were treated with Epi, L-NAME, or Epi and L-NAME and western blots were used to determine relative protein levels. (A) p-sirtuin-1, sirtuin-1, and β -tubulin protein content; (B) total sirtuin-1 and p-sirtuin-1 levels; (C) the p-sirtuin-1/sirtuin-1 ratio. Protein levels were normalized against β -tubulin. (Values are expressed as the mean $\pm$ SEM, $n = 3$ per group, * $p < 0.05$ vs. young control, ^ vs. aged control). (-)-Epicatechin = Epi, SIRT1 = sirtuin-1.

Fig. 4.

Effects of aging and (-)-epicatechin treatment on protein acetylation. Young and aged cells were treated with Epi, L-NAME, or Epi and L-NAME and western blots were used to determine relative protein levels. (A) Total protein acetylation in young and aged cells using anti-acetylatedlysine antibody and normalized against β-tubulin. (B) Immunoprecipitation using an antibody against eNOS to evaluate acetylation levels and its association with sirtuin-1. (C) Acetylated and sirtuin-1 associated with eNOS levels were normalized against β-tubulin. (Values are expressed as the mean ± SEM; $n = 3$ per group, * $p < 0.05$ vs. young control, and ^ vs. aged control). Acetylated lysine = Ac-Lys, (-)-epicatechin = Epi, sirtuin-1 = SIRT1.

Fig. 5.

Effects of aging and (–)-epicatechin treatment on mitochondria related protein levels (mitofilin, complex V, and TFAM). Young and aged cells were treated with Epi, L-NAME, or Epi and L-NAME and western blots were used to determine relative protein levels. (A) Representative protein levels of TFAM, mitofilin, and complex V. (B) Quantification of TFAM, mitofilin, and complex V. (Values are expressed as the mean ± SEM; $n = 3$ per group, * $p < 0.05$ vs. young control, ^ vs. aged control). (–)-Epicatechin = Epi.

Fig. 6.

Effects of aging and (-)-epicatechin on mitochondrial density and function. Young and aged cells were treated with Epi, L-NAME, or Epi and L-NAME. Quantification of complex IV (A) and II (B) protein levels by ELISA. Citrate synthase activity levels in young and aged treated cells (C). Changes in activity were normalized against protein content. Quantification of MitoTracker Green fluorescence in a microplate system (D). Fluorescence levels are expressed in arbitrary fluorescence units and were normalized against cell density. (Values are expressed as the mean $\pm$ SEM; $n = 5$ per group, * $p < 0.05$ vs. young control, and ^ vs. aged control). Arbitrary fluorescence units = AFU, (-)-epicatechin = Epi, MitoTracker = MT.

Fig. 7.

Effects of aging and (-)-epicatechin treatment on nitric oxide (NO) levels, systemic blood pressure and the vasodilatory capacity of aortic rings. (A) Systolic blood pressure as measured by tail cuff. (B) NO levels in control and treated young and aged rats. Comparison of acetylcholine induced vasodilatory effects on young (C) and aged (D) aortic rings and responses obtained by 15 days of pretreatment with (-)-epicatechin. (Values are expressed as the mean $\pm$ SEM; $n = 6$ per group, * $p < 0.05$ vs. young control, and ^ vs. aged control). Control = Ctrl, (-)-epicatechin = Epi.

Fig. 8.

Effects of aging and (-)-epicatechin treatment on p-eNOS levels and eNOS acetylation in young and aged rats as detected by immunofluorescence analysis. (A) Immunofluorescence of p-eNOS (green staining) in the endothelium of aortic rings as induced by 15 days pretreatment of animals with Epi or vehicle (control animals). Cell nuclei are stained blue. (B) Quantification of the p-eNOS immunofluorescence levels detected. (C) Immunofluorescence of eNOS (green) and acetylated-lysine (red) in the endothelium of aortic rings of vehicle and Epi treated young and aged rats ($n = 6$ per group, * $p < 0.05$ vs. young control, and ^ vs. aged control). Arbitrary fluorescence units (AFU), control = Ctrl, (-)-epicatechin = Epi.